|
2026 Journal Article Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunctionGiri, Rabina, Lee, Minyi, Magor, Graham, Bergot, Anne-Sophie, He, Yaowu, Kryza, Thomas, Khan, Tashbib, Schreiber, Veronika, Gordon, Robert J., Zagani, Rachid, Hasnain, Sumaira Z., Lourie, Rohan, Ewing, Adam, Hooper, John D., Thomas, Ranjeny, Florin, Timothy H., Perkins, Andrew, Gala, Manish and Begun, Jakob (2026). Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction. Cellular and Molecular Gastroenterology and Hepatology, 20 (2) 101659, 1-20. doi: 10.1016/j.jcmgh.2025.101659 |
|
2025 Journal Article Cost-effective inflammatory bowel disease flare pathway with nurse-led triage and rapid access intestinal ultrasound reduces hospital resource use with high patient satisfactionFernandes, Richard Gareth, Khoo, Emi, Jensen Harris, Heidi, Gilmore, Robert, Khaing, Myat Myat, Ennever, Jenny, Mullen, Kaity, Begun, Jakob and An, Yoon-Kyo (2025). Cost-effective inflammatory bowel disease flare pathway with nurse-led triage and rapid access intestinal ultrasound reduces hospital resource use with high patient satisfaction. Journal of Crohn's and Colitis, 19 (12) jjaf221. doi: 10.1093/ecco-jcc/jjaf221 |
|
2025 Journal Article Australian real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's Disease: Results of the AURORA Study, including the ANZIBD ConsortiumAn, Yoon‐Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Gilmore, Robert, Amiss, Anna, Pham, Hai, Ooi, Soong‐Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid, De Cruz, Peter, Li Wai Suen, Christopher F. D., Kariyawasam, Viraj, Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles P., White, Lauren S., Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford‐Smith, Graham and Begun, Jakob (2025). Australian real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's Disease: Results of the AURORA Study, including the ANZIBD Consortium. JGH Open, 9 (12) e70322, e70322. doi: 10.1002/jgh3.70322 |
|
2025 Journal Article Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigationsTan, Wei-Lian, Khoo, Emi, Khaing, Myat-Myat, Barr, Emily, Fernandes, Richard G., Pham, Hai, An, Yoon-Kyo and Begun, Jakob (2025). Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations. Journal of Gastroenterology and Hepatology, 40 (10), 2472-2481. doi: 10.1111/jgh.70019 |
|
2025 Journal Article Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from AustralasiaFernandes, Richard Gareth, Kim, Dong Hyun, Ruddick-Collins, Leonie, Vasudevan, Abhinav, Brownson, Anthony Robert, Ngoi, Benjamin, Lin, Chun-Chi, Haifer, Craig, Kim, Dae Sung, Swe, Ei, Wright, Emily Kate, Song, Eun Mi, Mahy, Gillian, Moore, Gregory Thomas, Lee, Hyun Seok, Kim, Hyun Soo, Zhang, Jennifer, Yan Mak, Joyce Wing, Lee, Jun, Lynch, Kate, Gazelakis, Kathryn, Rice, Katie, Kim, Kyeong Ok, Liu, Jing, Lilian Bracken, Lucy Mary, Garg, Mayur, Schultz, Michael, Clark, Nicholas, Cao, Qian ... An, Yoon-Kyo (2025). Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from Australasia. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2025.10.019 |
|
2025 Journal Article Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathyCai, Benjamin, Giri, Rabina, Cameron, Amy J., Rahman, M. Arifur, Small, Annabelle, Altmann, Christopher, Lim, Yenkai, Rehaume, Linda M., Morrison, Mark, Wechalekar, Mihir D., Begun, Jakob, Bergot, Anne-Sophie and Thomas, Ranjeny (2025). Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy. JCI Insight, 10 (17) e188028, 1-19. doi: 10.1172/jci.insight.188028 |
|
2025 Journal Article IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, AustraliaMahadevan, Uma, Jairath, Vipul, Begun, Jakob, Pudipeddi, Aviv, Garg, Mayur, De Cruz, Peter, Li Wai Suen, Christopher F. D., Choy, Matthew C., Con, Danny, Vaughan, Rose, Chetwood, John D., Clark, David A., Haifer, Craig, Sparrow, Miles P., Leong, Rupert and Mountifield, Réme (2025). IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia. Journal of Gastroenterology and Hepatology, 40 (S3), 3-22. doi: 10.1111/jgh.70020 |
|
2025 Journal Article Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyGilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research, 23 (3), 347-357. doi: 10.5217/ir.2024.00127 |
|
2025 Journal Article Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UCLi Wai Suen, Christopher F.D., Choy, Matthew C., Con, Danny, Cheng, Kaylene, Nigro, Julie, Breheney, Kerry, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William, Wright, Emily K., Taylor, Kirstin, Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson., Begun, Jakob, Radford-Smith, Graham L., Garg, Mayur, Martin, Neal, van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert W. ... De Cruz, Peter (2025). Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC. Gastroenterology, 170 (1), 118-131. doi: 10.1053/j.gastro.2025.07.020 |
|
2025 Journal Article Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loadingMathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading. Alimentary Pharmacology and Therapeutics, 62 (8), 799-808. doi: 10.1111/apt.70250 |
|
2025 Journal Article Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s diseaseGilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Swe, Ei, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research, 23 (4), 475-482. doi: 10.5217/ir.2024.00174 |
|
2025 Journal Article Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitisCui, Cedric S., Lerskiatiphanich, Titaya, Li, Xaria X., Giri, Rabina, Liu, Ning, Kumar, Vinod, Whittaker, Andrew K., Han, Felicity Y., Clark, Richard J., Begun, Jakob, Lee, John D. and Woodruff, Trent M. (2025). Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology, 182 (16), 3852-3869. doi: 10.1111/bph.70056 |
|
2025 Journal Article The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoringGilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's and Colitis 360, 7 (2) otaf028, 1-9. doi: 10.1093/crocol/otaf028 |
|
2025 Journal Article SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolomeTillett, Bree J., Dwiyanto, Jacky, Secombe, Kate R., George, Thomas, Zhang, Vivian, Anderson, Dovile, Duggan, Emily, Giri, Rabina, Loo, Dorothy, Stoll, Thomas, Morrison, Mark, Begun, Jakob, Hill, Michelle M., Gurzov, Esteban N., Bell, Kirstine J., Saad, Sonia, Barlow, Christopher K., Creek, Darren J., Chong, Chun Wie, Mariño, Eliana and Hamilton-Williams, Emma E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16 (1) 2893, 1-20. doi: 10.1038/s41467-025-58319-y |
|
2025 Journal Article Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutationsMoniruzzaman, Md, Wong, Kuan Yau, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2025). Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology and Translational Science, 8 (2), 543-556. doi: 10.1021/acsptsci.4c00644 |
|
2025 Journal Article Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease CoalitionAkyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2025). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089 |
|
2025 Journal Article Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case reportHuynh, David, Khaing, Myat Myat, Fernandes, Richard Gareth, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2025). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report. Case Reports in Gastroenterology, 19 (1), 1-6. doi: 10.1159/000542711 |
|
2025 Journal Article Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' ReplyMathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply. Alimentary Pharmacology and Therapeutics, 62 (8), 855-856. doi: 10.1111/apt.70338 |
|
2025 Journal Article Epidemiology and treatment patterns of fistulizing Crohn's disease in a large, real-world Australasian cohortMcNamara, Jack, Wilson, William, Pipicella, Joseph L., Ghaly, Simon, Begun, Jakob, Lawrance, Ian C., Gearry, Richard, Andrews, Jane M. and Connor, Susan J. (2025). Epidemiology and treatment patterns of fistulizing Crohn's disease in a large, real-world Australasian cohort. Gastro Hep Advances, 4 (4) 100594, 100594. doi: 10.1016/j.gastha.2024.100594 |
|
2024 Journal Article Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesRubin, David T., Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, Dignass, Axel, Abrahamovych, Orest, Abu-Farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Kharrat, Houssam Al, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico ... Zureikat, Firas (2024). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. The Lancet, 405 (10472), 33-49. doi: 10.1016/S0140-6736(24)01927-5 |
